“A unique study has been launched in Finland that will deepen the understanding about the origins of diseases and their treatment. The FinnGen study plans to tap into 500 000 unique blood samples collected by a nation-wide network of Finnish biobanks. The study is expected to continue for six years, securing funding of 69M€.”
The FinnGen research project is based on a public-private partnership between Finnish universities, biobanks, hospital districts, and several international pharmaceutical companies, to drive research, implementation, and economic development in the field of personalised medicine. The data created during the study can be used for prioritising drug targets based on genomic information, enabling more efficient drug development pipelines and better individualised drug treatment choices.
Around 290,000 individuals have already signed in, and in February 2019, some 146,000 datasets were already available for analytics.